{
    "organizations": [],
    "uuid": "9581599df75968a0c4a60ffad274563101fafa31",
    "author": "",
    "url": "https://www.reuters.com/article/brief-alder-biopharmaceuticals-announces/brief-alder-biopharmaceuticals-announces-offering-of-200-mln-convertible-senior-notes-idUSASB0C2PD",
    "ord_in_thread": 0,
    "title": "BRIEF-Alder Biopharmaceuticals Announces Offering Of $200 Mln Convertible Senior Notes",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 29 (Reuters) - Alder Biopharmaceuticals Inc:\n* ALDER BIOPHARMACEUTICALS, INC. ANNOUNCES OFFERING OF $200 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2025\n* ALDER BIOPHARMACEUTICALS - INTENDS TO USE PROCEEDS FROM OFFERING TO FUND DEVELOPMENT, COMMERCIALIZATION OF EPTINEZUMAB Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-29T14:16:00.000+02:00",
    "crawled": "2018-01-29T14:30:47.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "alder",
        "biopharmaceuticals",
        "inc",
        "alder",
        "biopharmaceuticals",
        "announces",
        "offering",
        "million",
        "convertible",
        "senior",
        "note",
        "due",
        "alder",
        "biopharmaceuticals",
        "intends",
        "use",
        "proceeds",
        "offering",
        "fund",
        "development",
        "commercialization",
        "eptinezumab",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}